Bureaucrats, checkuser, developer, editor, reviewer, Administrators, widgeteditor
1,951
edits
Changes
no edit summary
| base = valproic acid
| add = risperidone
| info = * Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases. * Risperidone is principally metabolized by CYP2D6 to an active metabolite. * This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination.
| start =
* Coadministration with risperidone may alter the serum concentrations of valproic acid, although data are conflicting.* Start according to the general dosing advice. Monitoring of the pharmacologic response and serum valproate levels is recommended.<ref name="drugscom">{{Drugscominteract|risperidone-with-valproic-acid-2019-0-2286-0|risperidone|valproic acid}}</ref>
| cave =
* Dose-related generalised oedema is reported. <ref> {{Pubmed|9921707|Sanders and Lehrer, Edema associated with addition of risperidone to valproate treatment. J Clin Psychiatry. 1998 Dec;59(12):689-90.}}</ref>
* Antipsychotics lower the seizure threshold and may antagonise the anticonvulsant effect of valproate. <ref name=”bazire”> Bazire S, Psychotropic Drug Directory 2007, HealthComm UK Limited, Aberdeen, 2007. </ref>
}}
